RMC 9805
Alternative Names: RMC-9805Latest Information Update: 21 Jun 2024
At a glance
- Originator REVOLUTION Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical study in cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 26 Feb 2024 Revolution Medicines plans a clinical trial for Cancer (Late-stage disease)
- 26 Feb 2024 Pharmacodynamics and adverse event data from a preclinical trial in cancer released by Revolution Medicines